Company Overview - UAB "Orkela" is a private limited liability company established on 24 September 2015, with its legal address in Vilnius and no branches or representative offices [1] - The main activities of the company include real estate development and construction, specifically a lyceum and hotel complex in Vilnius [2] Financial Highlights - In the first half of 2025, the company incurred costs of EUR 617.3 thousand for project development and EUR 1.9 million in financing costs, while generating revenue of EUR 163.0 thousand [3] - As of 30 June 2025, the company's total assets were valued at EUR 70,169 thousand, an increase from EUR 50,695 thousand as of 31 December 2024 [3] - The Loan to Cost (LTC) ratio as of 30 June 2025 was reported at 49.46% [4] Project Development Updates - The historical part of the complex was registered as 100% completed in April 2025 [5] - The Public Institution Modern School Center commenced operations in the complex in April 2025 [5] - In June 2025, Reitan Convenience Lietuva and TNS Kantar began their operations in the premises [5]

Core Insights - LIXTE Biotechnology Holdings, Inc. is focusing on developing novel cancer therapies targeting key cellular pathways, with a particular emphasis on high-need cancer indications that currently have limited treatment options [1][10] - The company's lead compound, LB-100, is being evaluated in clinical studies aimed at enhancing the effectiveness of chemotherapy and immunotherapy in treatment-resistant cancers [1][7] Colorectal Cancer - Colorectal cancer is one of the most prevalent cancers globally, with the drug market projected to exceed $18 billion by 2028; approximately 85% of cases are microsatellite-stable (MSS) and do not respond to existing immunotherapies [2][3] - LB-100 is being studied in combination with Roche's atezolizumab in a clinical trial at the Netherlands Cancer Institute, targeting MSS colorectal cancer patients [3] Ovarian Clear-Cell Carcinoma - Ovarian clear-cell carcinoma (OCCC) accounts for about 5-10% of ovarian cancer cases, with current treatments showing limited efficacy and poor long-term outcomes; the global market for ovarian cancer therapies was valued at over $2 billion in 2023 [3][4] - LB-100 is being evaluated in combination with GlaxoSmithKline's dostarlimab in a study at MD Anderson Cancer Center and Northwestern University, with interim data expected in Q4 2025 [4] Soft-Tissue Sarcoma - Soft-tissue sarcomas are rare cancers with limited treatment advancements; the global market for therapies is projected to reach $1.5 to $2 billion by 2030 [5] - A Phase 1b clinical study is being conducted in collaboration with the Spanish Sarcoma Group to evaluate LB-100 in combination with doxorubicin, aiming to enhance chemotherapy effectiveness [6] Development Strategy - LIXTE's clinical programs are aligned with significant commercial opportunities and unmet therapeutic needs, particularly in tumors with poor responses to current immunotherapies [7][8] - LB-100 is a first-in-class PP2A inhibitor designed to sensitize tumors to other treatments, including immune checkpoint blockade and standard chemotherapy [7][10]

Core Insights - CarMax is launching a new brand positioning with the tagline "Wanna Drive?" to emphasize its customer-centric, omni-channel car-buying experience [1][4][10] - The new approach aims to empower customers by allowing them to shop online, in-store, or switch between both seamlessly, setting a new standard in the used car retail industry [3][10] Brand Positioning - The new tagline "Wanna Drive?" replaces the previous tagline that had been in use for over 20 years, reflecting the evolution of CarMax and its commitment to customer empowerment [7][10] - CarMax's omni-channel experience allows customers to have control over their car-buying journey, providing clarity and confidence [10][12] Customer Experience - CarMax has achieved its highest Net Promoter Score since the rollout of its digital capabilities, indicating increased customer satisfaction, particularly among those using online and mixed shopping options [4][10] - The company emphasizes honesty, integrity, and innovation as core values that differentiate it from traditional and online-only dealers [4][10] Marketing Campaign - The campaign features the CarMax House Band, which represents the journey of car buying and selling, with creative spots designed to resonate with customers [11][12] - The marketing strategy includes a phased rollout across various platforms, including linear TV, streaming, social media, and audio [12]

Core Viewpoint - Vornado Realty Trust has announced an agreement to purchase the 623 Fifth Avenue office condominium for $218 million, aiming to reposition and redevelop it into a premier Class A boutique office building [2][3]. Acquisition Details - The acquisition involves a 36-story building with 382,500 rentable square feet, located above the flagship Saks Fifth Avenue department store [2]. - The building is currently 75% vacant, and Vornado plans to fully redevelop it [3]. Redevelopment Plans - Vornado intends to transform the 623 Fifth Avenue building to complement its existing holdings in the Plaza District and Park Avenue, which include several prominent addresses [3]. - The expected timeline for closing the acquisition is September 2025, with redevelopment completion targeted for 2027 [4].

Core Viewpoint - Catalyst Pharmaceuticals and SERB have reached a settlement with Lupin regarding the patent litigation over FIRDAPSE, allowing Lupin to market a generic version starting February 25, 2035, pending FDA approval [1][2]. Group 1: Settlement Agreement Details - The settlement agreement resolves ongoing patent litigation between Catalyst/SERB and Lupin concerning FIRDAPSE [2]. - Lupin is prohibited from marketing its generic version of FIRDAPSE in the U.S. before February 25, 2035, unless specific circumstances arise [2]. - The agreement includes the termination of all ongoing patent litigation related to FIRDAPSE patents in the U.S. District Court for the District of New Jersey [2]. Group 2: Company Background - Catalyst Pharmaceuticals is focused on developing and commercializing treatments for rare diseases and has a strong commitment to patient care [4]. - The company has been recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies [4].

MINNEAPOLIS, Aug. 25, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announces significant adoption by one of the world’s top five medical device leaders. Renowned for its cutting-edge diagnostic imaging systems, clinical software, and digital health solutions, this global innovator is recognized for advancing precision medicine and improving patient outcomes worldwide. There is a master services a ...

Safety and Pharmacokinetic Data Support Dosing ofART26.12 in Fed or Fasted Conditions Completion of Positive Single Ascending Dose Study with a Preliminary Food Effect Assessment Advances ART26.12 Toward Multiple Ascending Dose Trial SOLANA BEACH, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological co ...

Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals’ 90 trading day VWAP, and ...

MELBOURNE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a shareholder update including recent corporate developments and forecast for 2025/26. As a result of completing a recent initial public offering and up-listing to Nasdaq, the Company is entering a transformational stage as it prepares for the adv ...

Recent Purchases include 1,111 ETH at an Average Price of $4,341 Charlotte, NC, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Fundamental Global Inc (Nasdaq: FGNX, FGNXP) (the “Company” or “FG Nexus”), today announced its current ETH position increased to 48,545 ETH as of August 25, 2025, following a series of additional purchases and reflecting the positive impact of the Company’s initial staking rewards. The Company’s total ETH holdings are 48,545 representing approximately $230 million in an aggregate value (assumin ...